The Role of Continuing Cemiplimab in Second-Line Therapy After Progression

Opinion
Video

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.

Video content above is prompted by the following:

  • Discuss the role of continuing cemiplimab in second-line therapy after progression.
Recent Videos
2 experts in this video
2 experts are featured in this series.
2 experts in this video
2 experts in this video
1 expert in this video
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.